SEC Form 4 · accession 0001209191-17-058401
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elaine Castellanos
Officer — Principal Accounting Officer
Period of report
Sep 22, 2017
Accepted (ET)
Oct 31, 2017 · 10:52 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF1 | Sep 22, 2017 | C | 6,731 | — | A | 7,336 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class B common stockF1 | — | Sep 22, 2017 | C | 6,731 | D | — | — | Class A common stock | 6,731 | 0 | D |
Explanation of responses
- F1The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.